{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:45:04Z","timestamp":1786715104528,"version":"build-2736575974"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Asian J Androl"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/1008-682x.178483","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T02:26:57Z","timestamp":1457576817000},"page":"196","source":"Crossref","is-referenced-by-count":30,"title":["Indirect comparison between abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer: a systematic review"],"prefix":"10.4103","volume":"19","author":[{"given":"Tie","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Hao","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng-Yun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-An","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan-Liang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/1008-682X.178483-1","unstructured":"All Cancers (Excluding Non-melanoma Skin Cancer) Estimated Incidence, Mortality and Prevalence Worldwide in 2012. World Health Organization; 2012. Available from: http:\/\/www.globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx. [Last accessed on 2015 May 15]."},{"key":"key-10.4103\/1008-682X.178483-2","first-page":"27","volume-title":"Secondary hormonal therapy for advanced prostate cancer","author":"Lam","year":"2006","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.178483-3","first-page":"491","volume-title":"Castration-resistant prostate cancer: AUA guideline amendment","author":"Cookson","year":"2015","journal-title":"J Urol"},{"key":"key-10.4103\/1008-682X.178483-4","first-page":"242","volume-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","author":"Berthold","year":"2008","journal-title":"J Clin Oncol: official J Am Soc Clin Oncol"},{"key":"key-10.4103\/1008-682X.178483-5","first-page":"1368","volume-title":"Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer","author":"Italiano","year":"2009","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-6","first-page":"473","volume-title":"Enzalutamide versus abiraterone acetate for the treatment of men with metastatic castration-resistant prostate cancer","author":"Zhang","year":"2015","journal-title":"Exp Opin Pharmacother"},{"key":"key-10.4103\/1008-682X.178483-7","first-page":"3251","volume-title":"Castration-resistant prostate cancer: locking up the molecular escape routes","author":"Attar","year":"2009","journal-title":"Clin Cancer Res: official J Am Assoc Cancer Res"},{"key":"key-10.4103\/1008-682X.178483-8","first-page":"3876","volume-title":"Targeting continued androgen receptor signaling in prostate cancer","author":"Massard","year":"2011","journal-title":"Clin Cancer Res: official J Am Assoc Cancer Res"},{"key":"key-10.4103\/1008-682X.178483-9","first-page":"950","volume-title":"Novel molecular targets for the therapy of castration-resistant prostate cancer","author":"Agarwal","year":"2012","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-10","first-page":"983","volume-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.178483-11","first-page":"1187","volume-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.178483-12","unstructured":"Phillips B, Ball C, Sackett D, Badenoch D, Straus S, et al. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). Centre for Evidence-Based Medicine; 2009. Available from: http:\/\/www.cebm.net\/index.aspx?o=1025. [Last accessed on 2015 May 15]."},{"key":"key-10.4103\/1008-682X.178483-13","first-page":"1210","volume-title":"Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.178483-14","first-page":"1147","volume-title":"Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial","author":"Fizazi","year":"2014","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.178483-15","first-page":"34","volume-title":", Flaig TW, Molina A, Mulders PF, Fizazi K, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer","author":"Goodman","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"key-10.4103\/1008-682X.178483-16","first-page":"875","volume-title":"Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy","author":"Mulders","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-17","first-page":"429","volume-title":"Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial","author":"Sternberg","year":"2014","journal-title":"Ann Oncol: official J Eur Soc Med Oncol"},{"key":"key-10.4103\/1008-682X.178483-18","first-page":"152","volume-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"key-10.4103\/1008-682X.178483-19","first-page":"815","volume-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-20","first-page":"424","volume-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.4103\/1008-682X.178483-21","first-page":"1807","volume-title":"Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)","author":"Loriot","year":"2013","journal-title":"Ann Oncol: official J Eur Soc Med Oncol"},{"key":"key-10.4103\/1008-682X.178483-22","first-page":"1802","volume-title":"Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide","author":"Noonan","year":"2013","journal-title":"Ann Oncol: official J Eur Soc Med Oncol"},{"key":"key-10.4103\/1008-682X.178483-23","first-page":"30","volume-title":"Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone","author":"Schrader","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-24","first-page":"78","volume-title":"Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone","author":"Bianchini","year":"2014","journal-title":"Eur J Cancer"},{"key":"key-10.4103\/1008-682X.178483-25","first-page":"317","volume-title":"Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis","author":"Brasso","year":"2015","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-26","first-page":"234","volume-title":"Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer","author":"Schmid","year":"2014","journal-title":"Adv Ther"},{"key":"key-10.4103\/1008-682X.178483-27","first-page":"268","volume-title":"Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate","author":"Thomsen","year":"2014","journal-title":"Scand J Urol"},{"key":"key-10.4103\/1008-682X.178483-28","first-page":"968","volume-title":"Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment","author":"Badrising","year":"2014","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.178483-29","first-page":"23","volume-title":"Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients","author":"Azad","year":"2015","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-30","first-page":"34","volume-title":"The development of androgen-independent prostate cancer","author":"Feldman","year":"2001","journal-title":"Nat Rev Cancer"},{"key":"key-10.4103\/1008-682X.178483-31","first-page":"2176","volume-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","author":"Richards","year":"2012","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.178483-32","first-page":"2926","volume-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100","author":"End","year":"2013","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.178483-33","first-page":"866","volume-title":"Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301","author":"Montgomery","year":"2015","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-34","first-page":"29","volume-title":"Hormonal therapeutics enzalutamide and abiraterone acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel-an indirect comparison","author":"Tan","year":"2014","journal-title":"Clin Med Insights Oncol"},{"key":"key-10.4103\/1008-682X.178483-35","first-page":"578","volume-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"key-10.4103\/1008-682X.178483-36","first-page":"203","volume-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res: official J Am Assoc Cancer Res"},{"key":"key-10.4103\/1008-682X.178483-37","first-page":"3","volume-title":"The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer","author":"Pond","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-38","first-page":"3062","volume-title":"Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality","author":"Scosyrev","year":"2012","journal-title":"Cancer"},{"key":"key-10.4103\/1008-682X.178483-39","first-page":"263","volume-title":"Treating prostate cancer in elderly men: how does aging affect the outcome?","author":"Shelke","year":"2011","journal-title":"Curr Treat Options Oncol"},{"key":"key-10.4103\/1008-682X.178483-40","first-page":"706","volume-title":"A population-based study of prostate cancer chemotherapy","author":"Harris","year":"2011","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"key-10.4103\/1008-682X.178483-41","first-page":"655","volume-title":"Management of side effects of androgen deprivation therapy","author":"Grossmann","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"key-10.4103\/1008-682X.178483-42","first-page":"480","volume-title":"Drug safety is a barrier to the discovery and development of new androgen receptor antagonists","author":"Foster","year":"2011","journal-title":"Prostate"},{"key":"key-10.4103\/1008-682X.178483-43","first-page":"37","volume-title":"Towards random sequencing or precision medicine in castration-resistant prostate cancer?","author":"Loriot","year":"2014","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-44","first-page":"549","volume-title":"Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer","author":"Armstrong","year":"2012","journal-title":"Eur Urol"},{"key":"key-10.4103\/1008-682X.178483-45","first-page":"995","volume-title":"Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer","author":"Miyamoto","year":"2012","journal-title":"Cancer Discov"},{"key":"key-10.4103\/1008-682X.178483-46","first-page":"582","volume-title":"Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance","author":"Crona","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.4103\/1008-682X.178483-47","first-page":"265","volume-title":"Androgen receptor splice variants in the era of enzalutamide and abiraterone","author":"Nakazawa","year":"2014","journal-title":"Horm Cancer"},{"key":"key-10.4103\/1008-682X.178483-48","first-page":"3457","volume-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","author":"Hu","year":"2012","journal-title":"Cancer Res"},{"key":"key-10.4103\/1008-682X.178483-49","first-page":"3353","volume-title":"Molecular pathways: inhibiting steroid biosynthesis in prostate cancer","author":"Ferraldeschi","year":"2013","journal-title":"Clin Cancer Res: official J Am Assoc Cancer Res"}],"container-title":["Asian Journal of Andrology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:25:06Z","timestamp":1786713906000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/1008-682X.178483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017]]}},"alternative-id":["178483"],"URL":"https:\/\/doi.org\/10.4103\/1008-682x.178483","relation":{},"ISSN":["1008-682X"],"issn-type":[{"value":"1008-682X","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}